AB001. Vision impairment & repairment in diabetes

With the development of global industrialization,urbanization and changes of people’s lifestyle,Diabetes Mellitus,DM has become a serious worldwide health issue.The prevalence of diabetes in China is more than 10%.Due to the huge population base,China has surpassed the U.S.and India,becoming the country with the largest diabetic population in the world.Diabetic retinopathy(DR)is one of the most common complications of DM.The latest epidemiological survey shows that 17.8-29.2%of China’s diabetes patients developed DR,and it has become the leading cause of blindness in adults over the age of 40.Despite the continued emergence of new medicine and treatment in the past ten years,and a large number of global clinical trials have been carried out,we still couldn’t prevent the occurrence and development of DR.Microvascular damage caused by DM has been a top priority in the prevention and treatment of diabetic complications.Chinese government attaches great importance to the prevention and treatment of DR and has included it into China’s plan of the prevention and treatment of blindness.In this presentation,I’m going to focus on the pathogenesis of DR,especially the relationship between immune inflammatory response and DR.Major challenges and solutions in clinical treatment were discussed as well.

Post-infarct cardiac injury, protection and repair:roles of non-cardiomyocyte multicellular and acellular components

Following myocardial infarction(MI), cardiomyocytes and infarct size are the focus of our attention when evaluating the extent of cardiac injury, efficacy of therapies or success in repairing the damaged heart by stem cell therapy. Numerous interventions have been shown by pre-clinical studies to be effective in limiting infarct size, and yet clinical trials designed accordingly have yielded disappointing outcomes. The ultimate goal of cardiac protection is to limit the adverse cardiac remodeling. Accumulating studies have revealed that post-infarct remodeling can be attenuated without infarct size limitation. To reconcile this, one needs to appreciate the significance of various cellular and acellular myocardial components that, like cardiomyocytes, undergo significant damage and dysfunction, which impact the ultimate cardiac injury and remodelling. Microvascular injury following ischemia-reperfusion may influence infarct size and promote inflammation. Myocardial injury evokes innate immunity with massive inflammatory infiltration that, although essential for the healing process, exacerbates myocardial injury and damage to extracellular matrix leading to dilative remodeling. It is also important to consider the multiple non-cardiomyocyte components in evaluating therapeutic efficacy. Current research indicates the pivotal role of these components in achieving cardiac regeneration by cell therapy. This review summarizes findings in this field, highlights a broad consideration of therapeutic targets,and recommends cardiac remodeling as the ultimate target.